RCKT
NASDAQ · Biotechnology
Rocket Pharmaceuticals Inc
$3.44
+0.03 (+0.88%)
Open$3.39
Previous Close$3.41
Day High$3.53
Day Low$3.33
52W High$5.45
52W Low$2.53
Volume—
Avg Volume1.68M
Market Cap390.37M
P/E Ratio—
EPS$-1.88
SectorBiotechnology
Analyst Ratings
Buy
20 analysts
Price Target
+390.4% upside
Current
$3.44
$3.44
Target
$16.87
$16.87
$13.87
$16.87 avg
$23.44
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 67.67M | 66.73M | 71.52M |
| Net Income | -17,020,193 | -15,934,880 | -16,470,876 |
| Profit Margin | -25.2% | -23.9% | -23.0% |
| EBITDA | -23,292,743 | -22,716,839 | -22,207,941 |
| Free Cash Flow | -11,691,320 | -15,075,459 | -16,131,538 |
| Rev Growth | +1.5% | +16.6% | +10.7% |
| Debt/Equity | 1.36 | 1.21 | 1.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |